title: Therapeutic effects of one-year alendronate treatment in three cases of osteoporosis with parietal thinning of skull.
abstract: We studied the therapeutic effects of one-year alendronate treatment in three cases (two males and one female) of osteoporosis with parietal thinning of skull. Plain radiography and three dimensional computed tomography revealed asymmetric external thinning of the posteromedial part of the bilateral parietal bones. Technetium-99m methylenediphosphate bone scintigraphy did not show any changes in these three cases. Pretreatment levels of urinary type I collagen cross-linked N-telopeptides (NTX) in all three cases were high compared to the normal range. Pretreatment levels of serum bone-specific alkaline phosphatase (BAP) in the two male patients were high in contrast to the normal values in the female patient. Pretreatment mean bone mineral density (BMD) values of the 2nd to 4th lumbar vertebrae (L2-4BMD), head BMD, femoral neck BMD, and whole body BMD of all three patients were low compared with the respective normal ranges. One-year alendronate treatment decreased both urinary NTX and serum BAP in all three cases to normal values. Treatment also increased the whole body BMD in all three cases, the L2-4BMD of the female patient, the femoral neck BMD of the female patient and one male patient, and the head BMD of the female patient when compared to pretreatment levels.
authors.affiliation: Department of Orthopedics, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.
authors.forename: Shinjiro
authors.initials: S
authors.lastname: Takata
authors.forename: Shoichiro
authors.initials: S
authors.lastname: Takao
authors.forename: Shusaku
authors.initials: S
authors.lastname: Yoshida
authors.forename: Fumio
authors.initials: F
authors.lastname: Hayashi
authors.forename: Natsuo
authors.initials: N
authors.lastname: Yasui
mesh_terms: D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D010294:Parietal Bone / Q000000981:diagnostic imaging*; D011859:Radiography; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D019275:Radiopharmaceuticals; D019386:Alendronate; D013669:Technetium Tc 99m Medronate